董事会秘书负责办理上市公司内幕信息知情人的登记入档和报送事宜，证 券事务部为公司内幕信息的管理、登记、披露及备案的日常工作部门。董事长 与董事会秘书应当对内幕信息知情人档案的真实、准确和完整签署书面确认意 见。 第三条 公司的董事、高级管理人员和公司的各部门、子公司及相关人员 都应配合做好内幕信息的登记备案工作，并采取必要措施，在内幕信息公开前 将该信息的内幕知情人范围控制在最小范围内。 老百姓大药房连锁股份有限公司 内幕信息知情人登记管理制度 （二〇二五年八月二十五日，第五届董事会第十次会议审议通过） 第一章 总则 第一条 为规范老百姓大药房连锁股份有限公司（以下简称"公司"）的内 幕信息管理，加强内幕信息保密工作，维护信息披露公开、公平、公正的原则， 防范内幕信息泄露及内幕信息交易，根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司治理准则》《上市公司信息披露管理办法》《上海证券交 易所股票上市规则》《上市公司监管指引第5号——上市公司内幕信息知情人登记 管理制度》《上海证券交易所上市公司自律监管指引第2号——信息披露事务管理》 等有关法律、法规、以及《公司章程》的规定，特制定本制度。 第二 ...

Core Points - The document outlines the information disclosure management system of the company, aiming to ensure timely, fair, truthful, accurate, and complete information disclosure to protect investors' rights [1][2][3] - The company is committed to proactive disclosure of significant information that may impact stakeholders' decisions, while safeguarding sensitive financial data and trade secrets [1][2] Group 1: General Principles - The company establishes information disclosure principles in accordance with relevant laws and regulations, including the Company Law and Securities Law [1][2] - Information disclosure must be conducted through designated channels, ensuring accessibility for the public [1][2] Group 2: Disclosure Formats and Content - Regular reports, including annual and interim reports, must be disclosed within specified timeframes, with annual reports due within four months after the fiscal year-end and interim reports within two months after the first half of the fiscal year [2][3] - The content of annual reports includes company basic information, major accounting data, stock and bond issuance details, shareholder information, and significant events affecting the company [2][3][4] Group 3: Responsibilities and Procedures - The board of directors must approve regular reports, and financial information must be audited by a qualified accounting firm [4][5] - The company must disclose significant events that could impact stock prices immediately, detailing the event's cause, current status, and potential effects [6][12] Group 4: Management of Disclosure - The company's securities affairs department is responsible for managing daily disclosure tasks and ensuring compliance with regulations [34][35] - The board secretary plays a crucial role in coordinating disclosure activities and ensuring that all relevant information is accurately reported [35][36] Group 5: Confidentiality and Compliance - Individuals with access to undisclosed information are considered insiders and must maintain confidentiality to prevent unauthorized trading [58][59] - The company must implement measures to control the dissemination of insider information and ensure compliance with regulatory requirements [60][61]

湖南启元律师事务所 关于老百姓大药房连锁股份有限公司 限售期及预留授予部分第二个解除限售期解除限售条 件未成就及回购注销剩余限制性股票、调整回购价格 的 法律意见书 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410000 电话：（0731）82953-778 传真：（0731）82953-779 网站：www.qiyuan.com 致：老百姓大药房连锁股份有限公司 湖南启元律师事务所（以下简称"启元"或"本所"）接受老百姓大药房连 锁股份有限公司（以下简称"老百姓""公司"或"上市公司"）的委托，担任 老百姓 2022 年限制性股票激励计划（以下简称"本次激励计划""本激励计划" 或"激励计划"）的专项法律顾问。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理 办法》（以下简称"《管理办法》"）等现行法律、法规和规范性文件以及《老 百姓大药房连锁股份有限公司章程》（以下简称"《公司章程》"）、《老百姓 大药房连锁股份有限公司 2022 年限制性股票激励计划（草案）》 （以下简称"《激 励计划（草 ...

Core Viewpoint - The company has adjusted the repurchase price of its 2022 restricted stock incentive plan, reflecting changes due to cash dividends and compliance with relevant regulations [5][6][7]. Decision Procedures and Disclosure - The company held board and supervisory meetings to review and approve the adjustment of the repurchase price, ensuring independent opinions were provided by independent directors [1][2]. - The company conducted internal announcements and did not receive any objections during the public notice period [2]. Adjustment Reasons and Results - The adjustment of the repurchase price was necessitated by the distribution of cash dividends of 0.08 yuan per share, which was completed on July 14, 2025 [5][6]. - The repurchase price was adjusted from 11.685 yuan per share to 11.605 yuan per share, in accordance with the incentive plan's provisions [6]. Impact on the Company - The adjustment aligns with the relevant laws and regulations, ensuring no harm to the company or its shareholders, and is not expected to materially affect the company's financial status or operational results [6][7]. Supervisory and Legal Opinions - The supervisory board confirmed that the adjustment complies with the necessary legal frameworks and does not harm the interests of the company or its shareholders [7]. - Legal opinions from Hunan Qiyuan Law Firm affirmed that the adjustment has received the required approvals and adheres to relevant regulations [7].

Group 1 - The company announced the repurchase and cancellation of 1,205,377 restricted stocks from its 2022 incentive plan due to 32 individuals leaving for personal reasons and performance not meeting standards [1] - Following the repurchase, the company's registered capital will decrease by 1,205,377 yuan [1] - Creditors have a 30-day period from receiving the notice, or 45 days from the announcement date, to claim debts or request guarantees [1][2] Group 2 - Creditors must submit written requests along with relevant documentation to the company to claim debts or seek guarantees [2]

Core Viewpoint - The company has decided to repurchase and cancel a total of 1,205,377 restricted shares from its 2022 incentive plan due to the departure of 32 employees and underperformance in meeting company-level targets [1][7][8] Summary by Sections 1. Background of the Repurchase - The company held meetings on August 25, 2025, where the board and supervisory committee approved the repurchase of remaining restricted shares from the 2022 incentive plan [1] - The total amount for the repurchase is 14,889,399.25 yuan, sourced from the company's own funds [6] 2. Details of the Incentive Plan - The 2022 incentive plan included provisions for the approval and implementation of the plan, which was publicly disclosed and reviewed by independent directors [2][3] - The plan faced adjustments due to the departure of employees and performance issues, leading to the decision to cancel the restricted shares [5][7] 3. Repurchase Details - The repurchase involves 1,205,377 shares, with a repurchase price of 11.605 yuan per share, which includes interest from the People's Bank of China [6] - The repurchase will not affect the company's financial status or operational results significantly [7] 4. Impact on Share Structure - Following the repurchase, the company's total share structure will change, with the number of restricted shares decreasing to zero, while the number of unrestricted shares remains at 758,890,236 [6] 5. Future Actions - The company will proceed with necessary legal and regulatory procedures related to the repurchase and will ensure timely disclosure of information [8]

（一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 监事会认为： 证券代码：603883 证券简称：老百姓 公告编号：2025-039 老百姓大药房连锁股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 一、监事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日 发出召开第五届监事会第七次会议的通知，会议于 2025 年 8 月 25 日以现场表 决的方式召开。会议应参与表决的监事 3 名，实际参与表决的监事 3 名。本次 会议经过了适当的通知程序，会议程序符合《公司法》等有关法律法规及《公 司章程》的规定，会议及通过的决议合法有效。 二、监事会会议审议情况 会议审议并通过了如下议案： （1）公司2025年半年度报告编制和审议符合法律、法规、《公司章程》和 公司内部管理制度的规定。 （2）半年度报告的内容和格式符合中国证监会和上海证券交易所的有关规 定和要求，所包含的半年度报告能全面、真实地反映公司2025年半年度经营和 财务管理状况。 （3）未发现参 ...

证券日报网讯 8月25日晚间，老百姓发布公告称，2025年半年度公司实现营业收入10，774，312，515 元，同比下降1.51%；归属于上市公司股东的净利润为397，863，893元，同比下降20.86%。 （文章来源：证券日报） ...

Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of the year, attributing the decrease to changes in business operations and increased costs [1] Financial Performance - The company achieved operating revenue of 10.774 billion yuan, a year-on-year decrease of 1.51% [1] - The net profit attributable to shareholders was 398 million yuan, reflecting a year-on-year decline of 20.86% [1] Business Operations - The decline in net profit is primarily due to an increase in the sales proportion of new retail business, which led to a decrease in gross margin compared to the previous year [1] - There was also an increase in research and development expenses compared to the same period last year, contributing to the overall decline in profitability [1]

（文章来源：证券日报） 证券日报网讯 8月25日晚间，老百姓发布公告称，公司第五届监事会第七次会议审议通过了《关于公司 及其摘要的议案》等多项议案。 ...